Duke agrees to pay $112.5 million to settle allegation it fraudulently obtained federal research funding

Seth Thomas Gulledge
Triangle Business Journal
Originally posted March 25, 2019

Duke University has agreed to pay $112.5 million to settle a suit with the federal government over allegations the university submitted false research reports to receive federal research dollars.

This week, the university reached a settlement over allegations brought forward by whistleblower Joseph Thomas – a former Duke employee – who alleged that during his time working as a lab research analyst in the pulmonary, asthma and critical care division of Duke University Health Systems, the clinical research coordinator, Erin Potts-Kant, manipulated and falsified studies to receive grant funding.

The case also contends that the university and its office of research support, upon discovering the fraud, knowingly concealed it from the government.

According to court documents, Duke was accused of submitting claims to the National Institute of Health (NIH) and Environmental Protection Agency (EPA) between 2006-2018 that contained "false or fabricated data" cause the two agencies to pay out grant funds they "otherwise would not have." Those fraudulent submissions, the case claims, netted the university nearly $200 million in federal research funding.

“Taxpayers expect and deserve that federal grant dollars will be used efficiently and honestly. Individuals and institutions that receive research funding from the federal government must be scrupulous in conducting research for the common good and rigorous in rooting out fraud,” said Matthew Martin, U.S. attorney for the Middle District of North Carolina in a statement announcing the settlement. “May this serve as a lesson that the use of false or fabricated data in grant applications or reports is completely unacceptable.”

The info is here.

Doctors In Maine Say Halt In OxyContin Marketing Comes '20 Years Late'

Patty Wight
npr.org
Originally posted February 13, 2018

The maker of OxyContin, one of the most prescribed and aggressively marketed opioid painkillers, will no longer tout the drug or any other opioids to doctors.

The announcement, made Saturday, came as drugmaker Purdue Pharma faces lawsuits for deceptive marketing brought by cities and counties across the U.S., including several in Maine. The company said it's cutting its U.S. sales force by more than half.

Just how important are these steps against the backdrop of a raging opioid epidemic that took the lives of more than 300 Maine residents in 2016, and accounted for more than 42,000 deaths nationwide?

"They're 20 years late to the game," says Dr. Noah Nesin, a family physician and vice president of medical affairs at Penobscot Community Health Care.

Nesin says even after Purdue Pharma paid $600 million in fines about a decade ago for misleading doctors and regulators about the risks opioids posed for addiction and abuse, it continued marketing them.

The article is here.